Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Información del proyecto

RespiriTB

Identificador del acuerdo de subvención: 853903

DOI 10.3030/853903

Fecha de la firma de la CE 8 Mayo 2019

Fecha de inicio 1 Mayo 2019

Fecha de finalización 30 Abril 2027

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total € 9 962 900,00

Aportación de la UE € 6 840 000,00

Coordinado por

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands

Resultado final

Documents, reports (3)

Purified Mtb cytochrome report

The Purified Mtb cytochrome report will describe the methodology and confirmation of the purified cytochrome bc1, bc1:aa3, and bd

Continuous enzymatic assay and screening report

The continuous enzymatic assay and screening report will describe the assay, conditions and characterisation methodology of the continuous enzymatic assay for testing Mtr inhibitors and the application in the High Throughput Screening campaign.

In vitro activity of single HDT compounds report

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular MDRMtb strains in human cells

Websites, patent fillings, videos etc. (1)

Website RespiriTB online

The website developed for communication of all RespiriTB activities will be active and online.

Publicaciones

Non-peer reviewed articles (1)

Host‐directed therapy to combat mycobacterial infections*

Autores: Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Publicado en: Immunological Reviews, Edición 301/1, 2021, Página(s) 62-83, ISSN 0105-2896
Editor: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951